Perseus Proteomics (TYO:4882) and UBE have entered a collaborative research agreement focused on antibody-drug conjugates (ADC), which are used to kill cancer cells, according to its filing on Monday.
The partnership will enhance the development of PPMX-T004, an ADC, and explore additional ADCs using external drug discovery sources.
Their combined technologies will optimize antibody and drug/linker combinations for effective treatments.
Price (JPY): $610.00, Change: $+2.0, Percent Change: +0.33%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.